27-Hydroxycholesterol increases \u03b1-synuclein protein levels through proteasomal inhibition in human dopaminergic neurons

Jared Schommer,Travis Flick,Trevor Schommer,Jonah Lund,Othman Ghribi,Gurdeep Marwarha

doi:10.1186/s12868-018-0420-5

Jared Schommer, Travis Flick + Show 4 more

Open Access

https://doi.org/10.1186/s12868-018-0420-5

Copy DOI

Journal: BMC neuroscience	Publication Date: Apr 3, 2018
Citations: 21	License type: open-access

Affiliation: University of North Dakota

Abstract

BackgroundAccumulation of the α-synuclein (α-syn) protein is a hallmark of a group of brain disorders collectively known as synucleinopathies. The mechanisms responsible for α-syn accumulation are not well understood. Several studies suggest a link between synucleinopathies and the cholesterol metabolite 27-hydroxycholesterol (27-OHC). 27-OHC is the major cholesterol metabolite in the blood that crosses the blood brain barrier, and its levels can increase following hypercholesterolemia, aging, and oxidative stress, which are all factors for increased synucleinopathy risk. In this study, we determined the extent to which 27-OHC regulates α-syn levels in human dopaminergic neurons, the cell type in which α-syn accumulates in PD, a major synucleinopathy disorder.ResultsOur results show that 27-OHC significantly increases the protein levels, not the mRNA expression of α-syn. The effects of 27-OHC appear to be independent of an action through liver X receptors (LXR), its cognate receptors, as the LXR agonist, GW3965, or the LXR antagonist ECHS did not affect α-syn protein or mRNA levels. Furthermore, our data strongly suggest that the 27-OHC-induced increase in α-syn protein levels emanates from inhibition of the proteasomal degradation of this protein and a decrease in the heat shock protein 70 (HSP70).ConclusionsIdentifying 27-OHC as a factor that can increase α-syn levels and the inhibition of the proteasomal function and reduction in HSP70 levels as potential cellular mechanisms involved in regulation of α-syn. This may help in targeting the correct degradation of α-syn as a potential avenue to preclude α-syn accumulation.

Highlights

Accumulation of the α-synuclein (α-syn) protein is a hallmark of a group of brain disorders collectively known as synucleinopathies
Our results show that the differentiated neurons express dopamine transporter (DAT) and the DAT bands are present in absence or presence of the various concentrations of 27-OHC we used (Fig. 2A, B)
GW3965, an liver X receptors (LXR) agonist and ECHS, an LXR antagonist failed to elicit any change in α-syn protein or mRNA content suggesting there is no link between LXR and α-syn levels increase in the dopaminergic neuronal model

Summary

Introduction

Accumulation of the α-synuclein (α-syn) protein is a hallmark of a group of brain disorders collectively known as synucleinopathies. In support of our speculation of a link between synucleinopathies and 27-OHC are studies showing increased levels of a variety of cholesterol oxidation products (oxysterols), including 27-OHC, within the brains of patients with synucleinopathies [8, 18,19,20,21,22]. Oxysterol levels have been shown to be increased in the circulation of hypercholesterolemic individuals [23, 24], with aging [5, 25], and with oxidative stress [26], all of which are risk factors for PD Another interesting observation in support of a role of 27-OHC in brain neurodegeneration is that 27-OHC can cross the blood brain barrier while cholesterol cannot [19, 20, 27, 28]. Whether the accumulation of α-syn involves the inhibition of its degradation by 27-OHC is not known

Objectives

Methods

Results

Discussion

Conclusion